As Bristol lays off staffers and works through the painful loss of exclusivity for its megablockbuster blood cancer medicine Revlimid, the company is chalking up a win for its up-and-coming Reblozyl.Thanks to a new FDA approval, Bristol’s Reblozyl can be used as a first-line treatment for anemia in patients with very low- to intermediate-risk myelodysplastic […]
